97300 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Agonist effect on antigen
ANTI-LRP5 ANTIBODIES AND METHODS OF USE
#902Vector co-expressing vaccine and costimulatory molecules
#903Ameliorating systemic sclerosis with death receptor agonists
#904Anti-Axl antibodies
#905Gene signatures for determining ICOS expression
#906Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#907Modulators
#908Epitope for switching to T2 cell and use thereof
#909Vectors for expression of prostate-associated antigens
#910IL2R common gamma chain antibodies
#911Methods and compositions for promoting thermogenic potential
#912Epitope for switching to T1 cell and use thereof
#913Vector co-expressing vaccine and costimulatory molecules
#914Inotropic antibodies and therapeutic uses thereof
#915Antibodies that specifically bind PD-1 and methods of use
#916Compositions and methods for diagnosis and treatment of hepatic cancers
#917Anti-GITR antibodies and methods of use thereof
#918Anti-TrkB antibodies
#919Antibodies to ICOS
#920Methods to eliminate cancer stem cells by targeting CD47
#921Sodium pump antibody agonists and methods of treating heart disease using the same
#922ANTI-OX40 ANTIBODIES AND THEIR USES
#923Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1
#924METHODS AND COMPOSITIONS RELATING TO ANTI-TMIGD1/IGPR-2
#925Anti-CD137 antibodies and methods of use thereof
#926METHODS FOR THE TREATMENT OF EPILEPSY
#927Targeted immunotolerance
#928Anti-OX40 antibody and application thereof
#929Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
#930METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS
#931ICOS BINDING PROTEINS
#932BTLA agonist antibodies and uses thereof
#933Antibodies comprising modified heavy constant regions
#934Immunomodulatory antibodies
#935Bispecific antibodies specifically binding to PD1 and LAG3
#936Antibody Fc mutants with ablated effector functions
#937ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES
#938Anti-TNFRSF25 antibodies
#939Human TNFRSF25 antibody
#940ANTI RSPO ANTIBODIES AND METHODS OF USE
#941ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
#942Hinge modified antibody fragments and methods of making
#943COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS
#944SECRETED PROTEINS
#945Antibodies against human CD38
#946Methods and compositions related to functional polypeptides embedded in heterologous protein scaffolds
#947Anti-ICOS agonist antibodies and uses thereof
#948Methods and compositions for activation of T cells using nanoparticles conjugated with multiple ligands for binding receptors on T cells
#949Fully human antibody against human CD 137
#950Antigen-binding proteins that activate the leptin receptor
#951Antigen-binding proteins that activate the leptin receptor
#952Bispecific Constructs and Their Use in the Treatment of Various Diseases
#953Anti-transferrin receptor antibodies with tailored affinity
#954HETERODIMER BINDING PROTEINS AND USES THEREOF
#955HUMAN IMMUNE THERAPIES USING A CD27 AGONIST IN COMBINATION WITH ANOTHER IMMUNE AGONIST TO TREAT CANCER
#956ANTI-CD40 ANTIBODIES AND METHODS OF USE
#957Humanized or affinity-matured anti ang-2 antibody and uses thereof
#958ANTI-CD19 scFv (FMC63) POLYPEPTIDE AND USES THEREOF
#959Targeted immunotolerance
#960Immunological reagents
#961Anti-human 4-1BB antibodies and uses thereof
#962METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS
#963COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#964Combination immunotherapy for the treatment of cancer
#965Antibody therapeutics that bind TIM3
#966Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer
#967Bispecific antibody binding TRAIL-R2 and CD3
#968ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII
#969Anti-GITR Antibodies and Methods of Use Thereof
#970Antibodies directed against ICOS and uses thereof
#971Novel Treatment Methods Based on Multifunctional Molecules
#972ANTI-LAG-3 ANTIBODIES TO TREAT HEMATOLOGICAL MALIGNANCIES
#973Assays for detecting T cell immune subsets and methods of use thereof
#974Method for expansion of a population of cells with IL2R beta/common gamma chain antibodies
#975VISTA Agonist and Methods of Use
#976Stimulation via TLR4/MD-2 to reverse Type 1 diabetes
#977Anti-OX40 antibodies and methods of use
#978Method for in vivo expansion of T regulatory cells
#979MET ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF
#980MUSCARINIC ACETYLCHOLINE RECEPTOR BINDING AGENTS AND USES THEREOF
#981COMPOSITIONS AND METHODS FOR IMMUNOMODULATION
#982Monovalent anti-CD3 adjuvants
#983COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#984Methods for enhancing anti-tumor antibody therapy
#985Anti-GITR antigen-binding proteins and methods of use thereof
#986IL-2R beta/common gamma chain antibodies
#987RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
#988Modulation of tumor immunity
#989Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
#990Bispecific binding proteins that bind CD40 and mesothelin
#9914-1BB binding molecules
#992Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains
#993Drug-conjugated bi-specific antigen-binding constructs
#994AntiPlexin A1 agonist antibody
#995Human antibodies to PD-L1
#996Anti-human TIM-3 antibodies and methods of use thereof
#997Anti-TIGIT antibodies and methods of use
#998Anti-IL-5 antibodies
#999Bispecific antibodies
#1000Methods and compositions for treating fibrotic diseases
#1001Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination
#1002SIRP-α agonist antibody
#1003Anti-OX40 antibodies and their uses
#1004Epitope for switching to T17 cell and use thereof
#1005Fusion polypeptides capable of activating receptors
#1006Methods for expansion or depletion of t-regulatory cells
#1007Modulation of immune response using BTLA agonist antibodies
#1008Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
#1009ANTIBODIES TO CD40
#1010ANTI-cMET ANTIBODY
#1011Single domain antibodies targeting CD1d
#1012Humanized antibodies
#1013COMBINATION THERAPY WITH AN ANTI-ANG2 ANTIBODY AND A CD40 AGONIST
#1014PD-1 immune modulating agents
#1015Polypeptides
#1016Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
#1017Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#1018Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1
#1019Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
#1020FGFR1 AGONISTS AND METHODS OF USE
#1021Beta-klotho binding proteins
#1022Therapeutic compositions for treatment of ocular inflammatory disorders
#1023Anti-ANG2 antibody
#1024Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
#1025Fusion Proteins for Modulating Regulatory and Effector T Cells
#1026ANTI-H7CR ANTIBODIES
#1027Anti-human vista antibodies and use thereof
#1028Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#1029Retroviral and lentiviral vectors
#1030ANTI-H7CR ANTIBODIES
#1031Nucleic acids encoding agonistic antibodies that bind CD40
#1032Fn14 binding proteins and uses thereof
#1033Multivalent and multiepitopic antibodies having agonistic activity and methods of use
#1034Therapeutic CD47 antibodies
#1035Therapeutic CD47 antibodies
#1036COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
#1037Treatment of ocular disease
#1038FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them
#1039CD27 AGONISTS
#1040Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
#1041ICOS BINDING PROTEINS
#1042SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
#1043Antigen binding complex having agonistic activity and methods of use
#1044Markers of acute myeloid leukemia stem cells
#1045Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
#1046Antigen binding molecules and methods of use thereof
#1047BISPECIFIC ANTIBODY BINDING TO TRAILR2 AND PSMA
#1048Antibodies specific for hyperphosphorylated tau and methods of use
#1049Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
#1050Anti-MERTK agonistic antibodies and uses thereof
#1051ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII
#1052Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#1053Methods and compositions related to modulators of eukaryotic cells
#1054BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
#1055Humanized anti-CD134 (OX40) antibodies and uses thereof
#1056REGENERATION OF AGED SATELLITE CELLS
#1057Sodium pump antibody agonists and methods of treating heart disease using the same
#1058Anti-coagulation factor XI antibodies
#1059Anti-GITR antibodies and uses thereof
#1060Anti-TNFRSF25 antibodies
#1061Bispecific antibodies against CD3 and CD20
#1062Factor H potentiating antibodies and uses thereof
#1063WNT SIGNALING AGONIST MOLECULES
#1064Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
#1065ANTI-CD19 scFv (FMC63) POLYPEPTIDE
#1066Anti-CD40 antibodies
#1067Blockers of the growth hormone receptor in disease prevention and treatment
#1068Bak binding proteins
#1069Trispecific and/or trivalent binding proteins
#1070Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereof
#1071Therapeutic agent for autoimmune diseases comprising PD-1 agonist
#1072Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
#1073Diagnostic of Obliterative Arteriopathies
#1074ICOS BINDING PROTEINS
#1075COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY
#1076Compositions and methods of use for augmented immune response and cancer therapy
#1077Antibodies against OX40 and uses thereof
#1078WNT signaling agonist molecules
#1079Anti-human vista antibodies and use thereof
#1080Anti-human vista antibodies and use thereof
#1081ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#1082ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#1083ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#1084Anti-human vista antibodies and use thereof
#1085Antagonistic DR3 Ligands
#1086COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF
#1087Methods Of Treatment
#1088Anti-OX40 antibodies and methods of using the same
#1089AGONISTIC ANTIBODY TO CD27
#1090IGF-1R antibody and its use as addressing vehicle for the treatment of cancer
#1091Method of treating CD155 expressing cancers
#1092Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
#1093Antibodies to CD40 with enhanced agonist activity
#1094Modulating Agonistic TNFR Antibodies
#1095COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
#1096Anti-CD40 antibodies
#1097Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
#1098GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF
#1099Anti-CD40 antibodies and methods of treating cancer having CD40+ tumor cells
#1100Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#1101ANTI-CD40 ANTIBODIES AND USES THEREOF
#1102Anti-CD40 antibodies
#1103Method of identifying anti-VISTA antibodies
#1104Antibodies directed against ICOS and uses thereof
#1105Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
#1106Method for In Vivo Expansion of T Regulatory Cells
#1107Combination therapies with anti CD40 antibodies
#1108Antibody therapeutics that bind CD137
#1109Immunological reagents
#1110Antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor
#1111Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
#1112Discovery of regulatory T cells programmed to suppress an immune response
#1113Methods for improving cardiac function by administering an antibody that activates APLNR
#1114MONOVALENT ANTI-CD3 ADJUVANTS
#1115Anti-FGFR3 antibodies and methods using same
#1116B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY MOLECULES
#1117ANTIBODY GUIDED VACCINES AND METHODS OF USE FOR GENERATION OF RAPID MATURE IMMUNE RESPONSES
#1118Anti-EGFR conformational single domain antibodies and uses thereof
#1119Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
#1120Ligands that potentiate the bioactivity of gonadotropins
#1121Ligands that potentiate the bioactivity of gonadotropins
#1122Human Antigen Binding Proteins That Bind To a Complex Comprising beta-Klotho and an FGF Receptor
#1123Anti-TIE2 antibodies and uses thereof
#1124Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#1125Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
#1126Anti-FGFR1c antibody-FGF21 fusion proteins
#1127ICOS binding proteins
#1128Secreted proteins
#1129CD89 ACTIVATION IN THERAPY
#1130Method of treating retinopathy with an anti-LRP5 antibody
#1131P2X4 antibodies and uses thereof
#1132THERAPEUTIC AGENT FOR SOLID CANCER
#1133Methods and Compositions for the Generation and Maintenance of Regulatory T Cells
#1134Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
#1135GALECTIN IMMUNOTHERAPY
#1136Induction of immunotolerance to improve acceptance of tissue derived from pluripotent stem cells
#1137Antibody Substituting for Function of Blood Coagulation Factor VIII
#1138Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#1139Anti-mGluR2 conformational single domain antibodies and uses thereof
#1140Compositions and methods for the treatment of immune related diseases
#1141Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies
#1142Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#1143Anti-Axl antibodies
#1144Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
#1145STEM CELL ENHANCING THERAPEUTICS
#1146METHODS FOR PREDICTING THE RADIOSENSITIVITY OF A CANCER TUMOR AND METHODS OF TREATING CANCER
#1147MEDICAMENTS, USES AND METHODS
#1148Dual receptor antagonistic antigen-binding proteins and uses thereof
#1149ANTIBODY DRUG CONJUGATES
#1150Methods of inhibiting platelet aggregation and preventing thrombosis using antibodies that bind (Na+K)-ATPase beta subunit
#1151Methods and compositions for treating autoimmune and inflammatory conditions
#1152Antigen-binding proteins that activate the leptin receptor
#1153REGULATORS OF ANAPLASTIC LYMPHOMA KINASE AND USES THEREOF
#1154METHODS AND COMPOSITIONS FOR TREATING ALLERGY AND INFLAMMATORY DISEASES
#1155Distinguishing antagonistic and agonistic anti B7-H1 antibodies
#1156Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist
#1157Agonistic antibodies specifically binding CD40 and methods of use
#1158Monoclonal antibodies to programmed death 1 (PD-1)
#1159Anti-tigit antibodies and methods of use
#1160NOVEL MULTISPECIFIC MOLECULES AND NOVEL TREATMENT METHODS BASED ON SUCH MULTISPECIFIC MOLECULES
#1161COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
#1162GITRL fusion proteins comprising a human coronin 1a derived trimerization domain
#1163Humanized anti-HLA-DR antibodies
#1164Engineered antibody FC variants
#1165APLNR modulators and uses thereof
#1166Anti-vista antibodies and fragments
#1167Immunostimulatory anti-CEACAM1 antibody
#1168VACCINE
#1169Stimulation via TLR4/MD-2 to reverse type 1 diabetes
#1170TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS
#1171Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
#1172Uses of a dual V region antibody-like protein
#1173Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of
#1174NUCLEIC ACID ENCODING BISPECIFIC ANTIBODIES
#1175Immunoactivating antigen-binding molecule
#1176MEDICAL USES OF CRTAM AGONISTS
#1177GITR ANTIGEN BINDING PROTEINS
#1178Multivalent and multispecific DR5-binding fusion proteins
#1179Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
#1180Anti-TLR4 antibodies and uses thereof
#1181T cell balance gene expression, compositions of matters and methods of use thereof
#1182Antibodies to CD40 with enhanced agonist activity
#1183Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#1184Hybrid constant regions
#1185Multispecific NK engager proteins
#11864-1BB BINDING MOLECULES
#1187BISPECIFIC CONSTRUCTS AND THEIR USE IN THE TREATMENT OF VARIOUS DISEASES
#1188Method of treating cancer using IL2R beta/common gamma chain antibodies
#1189Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1
#1190Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#1191ICOS binding proteins
#1192Therapeutic compositions for treatment of ocular inflammatory disorders
#1193Activation of (NA+K)-ATPase inhibits platelet aggregation and prevents thrombosis
#1194METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES
#1195Anti-CD40 antibodies
#1196Antibodies against OX40 and uses thereof
#1197Anti-OX40 antibodies
#1198Fusion proteins for modulating regulatory and effector T cells
#1199Protein binding domains stabilizing functional conformational states of GPCRs and uses thereof
#1200Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)